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COVID-19 VACCINES AND THEIR PITFALLS IN
INFORMED CONSENT
by YOUSEF HAIK* AND ELENI POLYMENOPOULOU*

ABSTRACT
The World Health Organization declared the coronavirus (COVID-19)
pandemic as a global health crisis. The search for a coronavirus vaccine
escalated to a global competition. Drugs for other diseases as well as new
formulations are proposed as potential candidates for the treatment or
intervention of coronavirus. Almost all pharmaceutically able countries are
pursuing potential vaccines. At the time of writing this article, two vaccines
are already marketed and tested with promising interim results. Both
vaccines use messenger RNA (mRNA) encapsulated in a lipid nanocarrier.
Under ordinary circumstances, clinical trial authorizations oblige sponsors
to disclose all risks to volunteers in order to formulate an informed
knowledgeable decision. This however has been subject to exceptions during
the pandemic. The mRNA-based vaccine has been rushed in unprecedented
record speed to human clinical efficacy evaluation. This raises a number of
questions related to the validity of volunteers’ free and informed consent.
The present article argues that informed consent of all risks as well as the
protection of volunteers’ personal data constitute concrete obligations under
human rights law that cannot be derogated from in times of emergency –
such as the COVID-19 pandemic. Furthermore, it suggests a risk governance
framework through blockchain for international vaccine testing clinical
trials.
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I. INTRODUCTION
The novel Coronavirus (Covid-19) is one of the deadliest viruses of the
recent past. It was first reported in December 2019, in the city of Wuhan,
which is situated in the province of Hubei in Central-East China. The virus
is a “newly identified pathogen,”1 most likely transmitted by human-tohuman contact2 and has been associated with products and visitors of the
Huanan seafood market.3 Its spread has been facilitated by the fact that
Wuhan is a “major air and train transportation hub of central China,” and
arguably also because the initial spread of the disease coincided with the
festivities of the Chinese Chunyun (i.e. the celebration of the lunar year
Spring festival).4 On 11 March 2021, the World Health Organization
(“WHO”) officially named Covid-19 a pandemic,5 as the number of Covid19 cases outside China increased 13-fold since January 2020, and the number
of affected countries tripled.6 The overall growth rate is worryingly high. By
way of illustration, on 25 January 2020, a total of 75,815 individuals had
been infected in Wuhan, the outbreak epicenter,7 whereas at the same time,
only 581 were reported globally to the WHO.8
Scientists and pharmaceutical companies have been racing to develop
vaccines. The Kaiser Permanente Washington Health Research Institute in
the United States was the first to develop a vaccine. Its first Phase 1 clinical

Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) (Feb.
28, 2020), https://www.who.int/docs/default-source/coronaviruse/who-china-joint-missionon-covid-19-final-report.pdf.
2Joseph T. Wu, Kathy Leung & Gabriel M. Leung, Nowcasting and Forecasting the Potential
Domestic and International Spread of the 2019-nCoV Outbreak Originating in Wuhan, China:
A Modelling Study, 395 LANCET 689, 689 (2020) (provisionally named 2019 novel coronavirus
(2019-nCoV) and now severe acute respiratory syndrome SARS CoV2).
3 Id. at 689, 691.
4 Id. at 690 (stating that the festivities began Jan. 10, 2020 and lasted for forty days).
5 WHO Director-General’s Opening Remarks at the Media Briefing on Covid-19, WORLD
HEALTH ORG. (Mar. 11, 2020), https://www.who.int/director-general/speeches/detail/whodirector-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
6Id.
7
See Wu, supra note 2, at 689, 693.
8 See Novel Coronavirus (2019 n-CoV): Situation Report - 3, WORLD HEALTH ORG. (Jan. 23,
2020), https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200123sitrep-3-2019-ncov.pdf.
1
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trial9 was conducted on March 16, 2020.10 ModernaTX, Inc also developed
a vaccine. It is a mRNA-based11 vaccine encapsulated in a lipid nanoparticle,
tested at an open-label trial.12 The trial, which was scheduled to take place at
only one location in the United States,13 aimed at recruiting forty-five healthy
volunteers over 6 weeks and ultimately designed to test the vaccine (mRNA1273).14 Pfizer, too, the largest global vaccine maker, teamed with the
German company BioNTech to start clinical trials on another mRNA
experimental vaccine that was developed at Fosun Pharma.15 This mRNA
vaccine, which emerged as a promising technology for vaccine development
due to its non-infectious characteristics, activates the immune system to
produce immune shields against the coronavirus.16
Many of these vaccines have been already tested, approved, and
marketed.17 The ones that have circulated in the market have proved to be

See generally LAWRENCE M. FRIEDMAN, CURT D. FURBERG, DAVID L. DEMETS, DAVID M.
REBOUSSIN & CHRISTOPHER B. GRANGER, FUNDAMENTALS OF CLINICAL TRIALS, 4-10
(Springer Int’l Pub. Switz., 5th ed. 2015) (explaining the four phases of clinical studies in
which human subjects are administered a new drug: Phase 1 is performed on healthy
volunteers to evaluate the risk of the new drug formulation; Phases 2 to 4, tests are done on
patients to evaluate the therapeutic effect, confirm the therapeutic effect and market approval,
respectively).
10See NIH Clinical Trial of Investigational Vaccine for COVID-19 Begins, NAT’L INST. OF
ALLERGY AND INFECTIOUS DISEASES, (Mar. 16, 2020), https://www.niaid.nih.gov/newsevents/nih-clinical-trial-investigational-vaccine-covid-19-begins.
11 See generally Alexandre Jose Christino Quaresma, Rachel Sievert & Jeffrey A. Nickerson,
Regulation of mRNA export by the PI3 kinase/AKT signal transduction pathway, 28 MBOC
1208, 1208 (2013) (explaining that mRNA messenger ribonucleic acid is the single-stranded
intermediary that transfers genetic information from the DNA to the cytoplasm).
12 See generally supra note 9, at 241-242, 501 (stating that open label trial is a type of clinical
trial where both the researcher and the volunteer are aware which drug is being administered
to volunteers).
13 Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis
of SARS-CoV-2 Infection (COVID-19), U.S. NAT’L LIBR. OF M ED. (Feb. 25, 2020),
https://clinicaltrials.gov/ct2/show/NCT04283461.
14 U.S. Patent No. 10,577,630 (issued Mar. 3, 2020).
15 Clinical trials for COVID-19 vaccine start, millions of dollars at stake, LIVEMINT,
https://www.livemint.com/news/world/clinical-trials-for-covid-19-vaccine-start-millions-ofdollars-at-stake-11584618436860.html (last updated Mar. 19, 2020, 05:45 PM).
16 The Pfizer-BioNTech COVID-19 Vaccine U.S. Distribution Fact Sheet, PFIZER.COM
(Nov.
20,
2020),
https://www.pfizer.com/news/hottopics/covid_19_vaccine_u_s_distribution_fact_sheet.
17 Benjamin Mueller, U.K. Approves Pfizer Coronavirus Vaccine, a First in the West, N.Y.
TIMES (Dec. 2, 2020), https://www.nytimes.com/2020/12/02/world/europe/pfizercoronavirus-vaccine-approveduk.html#:~:text=LONDON%20%E2%80%94%20Britain%20gave%20emergency%20autho
rization,than%201.4%20million%20people%20worldwide.
9
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relatively successful, even against reported mutations of the virus.18 And yet,
a number of scientists have been expressing fears about the potential adverse
effects of these vaccines. Potential risks associated with vaccines containing
nano-carriers are generally greater than common vaccines. Clinical trials
employing nano-carriers are characterized by unknown efficacy, tolerability
and safety, thus posing uncertain and ambiguous risk assessment. The
uncertain nature of new mRNA vaccines loaded in nano-carriers poses
potential risks for volunteer participants.19 In addition, complications on
volunteers have already been reported at a trial stage. 20 By way of
illustration, shortly after the marketing of the first vaccines, the CDC
reported that healthy receivers of the Pfizer vaccine suffered from severe
allergic reactions.21 A case of a trial volunteer who presented a number of
symptoms including inflammation of the spinal cord was also reported.22
This paper explores the legal issues pertinent to these vaccinations
containing nanoparticles, especially trial participants’ rights in relation to
informed consent, and pharmaceutical companies’ obligations. It further
discusses ambiguous practices during the Covid-19 pandemic, such as those
related to fast-tracking approval processes (‘speedy trials’) and conducting
the vast majority of trials in the developing world. The following four
sections discuss more specifically: first, the extent to which unknown side
effects of unauthorized vaccines administered in clinical trials are covered
by individual consent (section 2). As this paper argues, a dynamic
interpretation of consent23 cannot overcome constraints emerging from
international human rights law and subsequent State obligations in relation
to the right to health. Secondly, we explore whether dilution of informed
consent is permissible during a state of emergency, such as the Covid-19
pandemic through speedy trials under the so-called regime of derogations
18

Apoorva Mandavilli, The Coronavirus Is Mutating. What Does That Mean for Us?, N.Y.
Times (Dec. 20, 2020), https://www.nytimes.com/2020/12/20/health/coronavirus-britainvariant.html.
19 Question and Answers on the interplay between the Clinical Trials Regulation and the
General Data Protection Regulation, EURO. COMM. DIR.-GEN. FOR HEALTH AND FOOD
SAFETY
(2014),
https://ec.europa.eu/health/sites/health/files/files/documents/qa_clinicaltrials_gdpr_en.pdf.
20 Rebecca Robbins et al., AstraZeneca Covid-19 vaccine study put on hold due to suspected
adverse reaction in participant in the U.K., STATNEWS (Sept. 8, 2020),
https://www.statnews.com/2020/09/08/astrazeneca-covid-19-vaccine-study-put-on-holddue-to-suspected-adverse-reaction-in-participant-in-the-u-k/.
21 COVID-19 Vaccines and Allergic Reactions, CTR. FOR DISEASE CONTROL (last updated Jan.
22,
2021),
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/allergicreaction.html.
22 Alle, supra note 20.
23 Jane Kaye et al., Dynamic Consent: A Solution to a Perennial Problem?, BRIT. MED. J.142
(2011).
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(section 3). Thirdly, we go on to examine whether and which remedies are
available to volunteers who suffer from those risks, both territorially as well
as extra-territorially in the case of outsourced trials (section 4). Last, the
paper examines whether the triggering of a State of emergency and the socalled derogation regime can serve as justification for the non-applicability
of human rights obligations related to clinical trials. In this respect, the paper
suggests that States do not have the right to derogate from the right to the
enjoyment of the highest attainable standards of health, even in situations of
emergency, such as Covid -19 (section 5). Ultimately, the paper suggests a
blockchain-based governance model for managing risks arising from clinical
trials involving new pharmaceutical technologies (section 6).

II. THE SCOPE OF INFORMED CONSENT IN CLINICAL TRIALS UNDER
HUMAN RIGHTS LAW
Informed consent manifests itself as a doctrine stemming from
individual autonomy and privacy. It has been crucial in the development of
medical ethics theories concerning liability in English and early American
law, including in tort and negligence.24 In the wording of the Appellate Court
of California as far as back as 1957:
A physician violates his duty to his patient and subjects himself to
liability if he withholds any facts which are necessary to form the
basis of an intelligent consent by the patient to the proposed
treatment… In discussing the element of risks a certain amount of
discretion must be employed consistent with the full disclosure of
facts necessary to informed consent. 25
For claims alleging lack of informed consent in overseas clinical trials,
US courts distinguish situations where lack of consent may be treated as a
battery claim not requiring injury, from situations where lack of informed
consent is best treated as a form of negligence requiring causation and actual
injury. Shloendorff v. Society of New York Hospital26 established the root
premise of true consent. It was stated that: “Every human being of adult years
and sound mind has a right to determine what shall be done with his own
Ruth R Faden & Tom L Beauchamp (eds), A History and Theory of Informed Consent 24ff
(1986).
25 Salgo v. Leland Stanford Board of Trustees, 154 Cal. App. 2d 560, 578 (1957).
26 Schloendorff v. Soc'y of New York Hosp., 211 N.Y. 125, 105 N.E. 92 (1914), abrogated
by Bing v. Thunig, 2 N.Y.2d 656, 143 N.E.2d 3 (1957)
24
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body.” True consent is “the informed exercise of a choice, which entails an
opportunity to evaluate knowledgeably the options available and risks.” 1 In
Helling v. Carey,27 the Court went on to note that the health care provider’s
compliance with the standards of protection as established by a reasonable,
prudent professional is necessary to shield him from negligence claims. The
average volunteer for evaluating the efficacy of a new mRNA vaccine nanocarrier has little to no understanding of the associated uncertainties and risks,
and only the developer of such vaccine “may” have the highest possible
knowledge of said risks. Thus, for the volunteers to reach an intelligent
informed decision they must necessarily rely on the expertise of the
developer.
Due to the difficulty to predict the potential adverse effect of mRNA
vaccine and its-nanocarrier constituents, informed consent is crucial. The
major technological challenges for wide spread application of encapsulated
mRNA are its instability, high innate immunogenicity and ineffective
delivery.28 These challenges were addressed by loading the vaccine into a
nano-carrier due to their small size (about 100-150 nano-meters), which
allows for free circulation and avoidance of the immune system.29 Under
human rights law, the right to informed consent in relation to medical
treatment and medical experimentation is implied in a variety of treaty
provisions, including the right to physical integrity;30 the right to private life,
specifically health information privacy;31 the right to health;32 freedom from

27

Helling v. Carey, 83 Wash. 2d 514, 519 P.2d 981 (1974), disapproved of by Barton v. Owen,
71 Cal. App. 3d 484, 139 Cal. Rptr. 494 (Ct. App. 1977)
28 Norbert Pardi et al., mRNA Vaccines - A New Era in Vaccinology, NAT. J. 261-279 (2018),
https://www.nature.com/articles/nrd.2017.243.pdf.
29 See Elvin Blanco et al., Principles of Nanoparticle Design for Overcoming Biological
Barriers
to
Drug
Delivery,
NAT.
J.
941-951
(2015),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978509/pdf/nihms805388.pdf.
30 International Covenant of Civil and Political Rights Article Seven, March 23, 1976.
31 International Covenant of Civil and Political Rights Article Seventeen, March 23, 1976; Cf.
also, ECtHR, X and Y v. the Netherlands, 26 March 1985, § 22, Series A No. 91 (noting that
Article Eight of the Convention and the concept of “private life” encompasses the physical
integrity).
32 International Covenant of Economic, Social, and Cultural Rights Article Twelve, January
3, 1976 guarantees the enjoyment of the highest attainable standard of physical and mental
health. Similarly worded provisions are found also in the International Convention on the
Elimination of All Forms of Racial Discrimination Article Five; Convention on the
Elimination of All Forms of Discrimination against Women Article Twelve; Convention on
the Rights of the Child Article Twenty-Four; San Salvador Protocol Article Ten; African
Commission of Human People‘s Rights Article Sixteen; European Social Charter Article
Eleven.

154

HASTINGS SCIENCE AND TECHNOLOGY LAW JOURNAL

Vol. 12:2

inhuman and degrading treatment (IDT);33 and the protection of the integrity
of the person, especially persons with disabilities.34 All these provisions shed
light on the legality of treatment without fully informed consent. The
International Covenant on Civil and Political Rights (ICPPR) was adopted
following the sore experiences of Nazi Germany and experiments on
prisoners and detained persons,35 referring specifically to the right to free and
informed consent for any medical experiments.36
References in the jurisprudence of UN treaty bodies, however, are still
scarce. The most relevant case before the CESCR to date is arguably Merino
Sierra v Spain,37 which was found to be inadmissible due to the facts having
taken place prior to the entry into force of the Optional Protocol to the
ICESCR. The complaint was based on article 12 of the International

33 International Covenant of Civil and Political Rights Article Two, March 23, 1976; European

Court of Human Rights Article Three. See N. v. the United Kingdom [GC], no. 26565/05, §
29, ECHR 2008 (regarding the suffering flowing from a naturally occurring illness
‘exacerbated by treatment stemming from measures for which the authorities can be held
responsible.’
34 See Convention on the Rights of Persons with Disabilities Article Fifteen: “No one shall be
subjected to torture or to cruel, inhuman or degrading treatment or punishment. In particular,
no one shall be subjected without his or her free consent to medical or scientific
experimentation” and Article Seventeen; Phil Fennell, ‘Article 15’ in: The UN Convention on
the Rights of Persons with Disabilities: A Commentary (Ilias Bantekas, Stein, Anastasiou eds,
OUP 2019). Also, indicatively, Committee on the Rights of Persons with Disabilities,
Concluding observations on the initial report of South Africa, CRPD/C/ZAF/CO/1, 23
October 2018, paragraph 32 (regarding forced sterilization and the administration of
experimental or new drugs and treatments on girls and women with disabilities without their
free and informed consent).
35 See The Nuremberg Code Article One, October 1946, See Art. 1 of Nuremberg Code, which
was emphasized in the context of: “Permissible Medical Experiments,” in Trials of War
Criminals before Nuremberg Military Tribunals under Control Council Law.
36 International Covenant of Civil and Political Rights Article Seven, March 23, 1976: “No
one shall be subjected to torture or to cruel, inhuman or degrading treatment or punishment.
In particular, no one shall be subjected without his free consent to medical or scientific
experimentation.”
37 Imelda Merino Sierra and Juan Luis Merino Sierra v. Spain, International Committee on
Economic, Social and Cultural Rights, App. No. 4/2014. Views adopted by the Committee
under the Optional Protocol to the International Covenant on Economic, Social and Cultural
Rights, UN Doc E/C.12/59/D/4/2014 (24 November 2016) para. 7 (regarding a lawsuit for
medical negligence, failure to provide treatment and lack of informed consent for medical
tests medical tests on a patient diagnosed with pancreatic cancer). Likewise, in LML, a
complaint relevant to lack of informed consent about the potential risks of a spinal surgery,
was found to be inadmissible. See, LML v. UK. Decision adopted by the Committee under
Article Two of the Optional Protocol, concerning communication No. 27/2015 (24 March
2017) (inadmissible) (regarding a patient subject to spinal surgery without having received
comprehensive information about the subsequent risks).
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Covenant on Economic Social and Cultural Rights (ICESCR) and the right
to health.38
The jurisprudence of the European Court of Human Rights (ECtHR)in a
number of cases related to medical procedures involving pharmaceutical
companies could also provide some guidance on the way informed consent
should be understood. Vaccination without informed consent is generally
considered by the ECtHR as a form of compulsory medical intervention
‘even if it is of a minor importance’.39 As such it amounts to an interference
with the right to respect for one’s private life ‘which includes a person’s
physical and psychological integrity, as guaranteed by Article 8(1)of the
Convention’.40 Yet, the question of the legitimacy of interference with
individual rights is subject to the usual balancing exercise undertaken by the
Court, including the necessity and proportionality tests. These tests typically
amount to the benefit of the State as public health considerations are
generally considered adequate justifications for an infringement to the right
to private life under article 8 of the Convention. In addition, the
jurisprudence of the Court in a number of cases related to persecution of
individuals who refused to undergo compulsory vaccination41 does not
support the suggestion that State authorities have an obligation to justify how
a particular vaccine is detrimental to one’s health. In Solomakhin, for
example, an individual was vaccinated for diphtheria while at the last stage
Id. at paragraph 8. The Committee on ESCR has expanded to include the right to be free
from medical experimentation and treatment without the patient’s consent. See also, CESCR,
General Comment 14: The Right to the Highest Attainable Standard of Health (Article 12),
UN Doc E/C.12/2000/4 (11 August 2000) para. 8–9 (noting that the Covenant recognises the
right to enjoy high standards of health, which represents a proposition that is largely
dependent on a series of positive obligations. These obligations are of a twofold nature: on
the one hand they require the provision of adequate health care services, while on the other
they oblige the authorities to satisfy the underlying determinants of health, including basic
shelter, food, water, sanitation, safe working environment, freedom from pollution, disease
prevention and others. This definition of the right to health with its two corresponding
components is broader than the definition of ‘health’ in the preamble to the Constitution of
the World Health Organization (WHO), which defines health as a ‘state of complete physical,
mental and social well-being and not merely the absence of disease or infirmity’).
39 See for example, Y.F. v. Turkey, no. 24209/94, ECHR 2003-IX at para 33 (‘a person’s bodily
integrity concerns the most intimate aspects of one’s private life, and that compulsory medical
intervention, even if it is of a minor importance, constitutes an interference with this right’).
40 Salvetti v. Italy (dec.), no. 42197/98, 9 July 2002, and Matter v. Slovakia, no. 31534/96, §
64, 5 July 1999.
41 Solomakhin v. Ukraine, App No 24429/03 (15 March 2012) para 38. Cf also, Boffa and 13
others v. San Marino, application no. 26536/95, Commission decision of 15 January 1998,
DR 92; also, Vavřička v. the Czech Republic, App Nos. 47621/13, 3867/14, 73094/14 et al
(relinquishment); Aleksandra Skerlevska against the former Yugoslav Republic of Macedonia,
Application no. 54372/15, lodged on 26 October 2015, Communicated on 12 June 2017
(pending).
38
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of an illness, following the spread of an epidemic in Eastern Ukraine.42 The
applicant claimed that the doctors had not sought his informed consent for
this particular vaccine, nor had they properly checked potential side effects.
According to the Court, ‘the applicant’s physical integrity could be said to
be justified by the public health considerations and necessity to control the
spread of infectious diseases’.43
Two safeguards seem to be applicable in this respect. Firstly, the Court
maintains that access to unauthorized vaccinations and experimental
products must be regulated, precisely because of the absence of European
consensus among European States on the matter. 44 Secondly, any
interference with individual health and the right to private life under article
8 should be accompanied by relevant precautions ‘to ensure that the medical
intervention would not be to the applicant’s detriment to the extent that
would upset the balance of interests between the applicant’s personal
integrity and the public interest of protection of the health of the
population’.45 Such precautions clearly should encompass precise
information about all potential risks. As emphasized by Judge Zupančič:
“Informed” consent implies that the patient in such circumstances must be
instructed as to all the potential risks of administering any kind of medical
treatment, which he must thereafter consent to in a genuinely informed way.
Failing that, we cannot speak of a full consent […].46 This is a particularly
important obligation in speedy trials. By way of example, Sinopharm’s
vaccine was tested on approximately a million people, as part of an
‘emergency-use program authorized by Beijing’.47 Such ‘fast track’

Solomakhin, supra note 39 at para 30 (regarding patients who were vaccinated ‘vaccinated
during the acute stage of an illness and that the doctors had not checked all relevant
contraindications to vaccination in his case’. In particular , the patients claimed that they had
been administered an expired vaccine of poor quality , as well as that this was done against
their will.
43 Solomakhin, supra note at para 36. The individual died subsequently from a heart attack.
44 Hristozov and others v. Bulgaria, App No. 47039/11 and 358/12 (13 November 2012) para
122 – 125 (regarding vaccination of an unauthorized vaccine on cancer patients, allowed
exceptionally for “compassionate use”). The ECtHR noting that national courts should strike
a ‘balance between the public interest and personal autonomy, sought to protect the health and
life of those concerned by preventing abuses and the risks accompanying the use of untested
products’).
45 Hristozov, supra note 42 at para 122 – 125
46 Solomakhin, supra note (concurring opinion of Judge Zupančič).
47
Ben Westcott & Sophie Jeong, Almost a Million People Have Been Given an Experimental
Chinese Coronavirus Vaccine, Pharmaceutical Giant Claims, CNN (Dec. 7, 2017), at 1,
https://www.cnn.com/2020/11/20/asia/china-sinopharm-vaccine-test-intl-hnk/index.html.
42
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approvals have sparked intense debate in medicine more generally48 and
medical ethics more specifically,49 as well as the media, 50 and are arguably
in contradiction with human rights standards on vaccine authorization and
informed consent due to the rapidity of procedures.

III. OUTSOURCING CLINICAL TRIALS: PITFALLS FOR INFORMED
CONSENT OBLIGATIONS
Before circulating in the market, vaccines are tested in different
segments of populations. This is not necessarily problematic – rather, it is a
necessary requirement to ensure a vaccine’s effectiveness against ‘all diverse
populations of the world.’51 A recent trend, however, has emerged involving
the outsourcing of clinical trials in locations outside the home state of large
multinational pharmaceutical companies. Both home states and foreign
states typically participate in the outsourced trials. The foreign state accepts
to participate in the outsourced trials as part of their healthcare obligations
to provide medications that is otherwise unavailable without such
participation (‘outsourcing trials’). The home state accepts to participate in
outsourced trials to have a pool of volunteers residing in other countries
(‘cross-border clinical trials’), particularly Brazil, China, India, South
Africa, the Middle East, and Eastern Europe.52 This raises a number of
See generally, Robert Steel, Lara Buchak & Nir Eyal, Why Continuing Uncertainties are
no Reason to Postpone Challenge Trials for Coronavirus Vaccines, 46 J MED ETHICS 808, 808
(2020), https://jme.bmj.com/content/medethics/46/12/808.full.pdf; contra Arnon Keren &
Ori Lev, Uncertainty, Error and Informed Consent to Challenge Trials of COVID-19
Vaccines,
46
J.
MED.
ETHICS
808,
813
(2020),
https://jme.bmj.com/content/medethics/46/12/813.full.pdf.
49 Jennifer O’Neill, The COVID-19 vaccine, informed consent and the recruitment of
volunteers, J. OF MED. ETHICS: BLOG (Nov. 3, 2020), https://blogs.bmj.com/medicalethics/2020/11/23/the-covid-19-vaccine-informed-consent-and-the-recruitment-ofvolunteers/.
50 Sui-Lee Wee & Elsie Chen, Vaccine Unproven? No Problem in China, Where People
Scramble
for
Shots,
N.Y.
TIMES
(Nov.
11,
2020),
https://www.nytimes.com/2020/11/17/business/china-coronavirus-vaccine-safety.html /.
51See 172 countries and multiple candidate vaccines engaged in COVID-19 vaccine Global
Access Facility, WHO (Aug. 24, 2020), https://www.who.int/news/item/24-08-2020-172countries-and-multiple-candidate-vaccines-engaged-in-covid-19-vaccine-global-accessfacility.
52
By way of example, see, Seth W. Glickman et al., Ethical and Scientific Implications of the
Globalization of Clinical Research, 360 NEW ENG. J. OF MED. 2792, 2793 (2009); see also,
Carolijn Terwindt, Health Rights Litigation Pushes for Accountability in Clinical Trials in
India, 16 HEALTH AND HUM. RTS. J. 84, 83 (2014); Benjamin Kagina, COVID-19 vaccine
48
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issues, including the lack of available and effective legal remedies in
volunteers’ own countries. In fact, cross-border clinical trials are often
viewed by volunteers as access to medical treatment that is otherwise
unavailable in their home states. Patient volunteers are less likely to question
the treatment procedure or the medication provided to them at no cost.53 It is
estimated that more than 50 percent of all clinical trials is conducted outside
the producers’ country of incorporation or headquarters.54 The US Federal
Drug Administration (FDA) approved over forty formulations of drugs55 that
employ nanotechnology either in its making of the active ingredient (e.g.,
sirolimus56) or encapsulating the active ingredient with a protective shell to
improve the efficacy and reduce side effects (e.g., liposomal formulation of
doxorubicin).57 The nano-enabled products that are approved by the FDA
receive wide international recognition and acceptance. For example, only 49
percent of Doxil,Ò known internationally as Caelyx,Ò and its family of similar
products are sold in the US market.58 In Saudi Arabia alone, there are to date
ten clinical trials utilizing DoxilÒ.59
Many actors are involved in a clinical trial of a new drug and in the
various phases of its administration. These include the drug-producing
company, the researchers, the research organizations conducting the trial
(which may be a public or private academic institution or a private
trials in Africa: what’s promising, and what’s problematic, THE CONVERSATION (Dec. 2, 2020),
https://theconversation.com/covid-19-vaccine-trials-in-africa-whats-promising-and-whatsproblematic-150967; and Jeffrey Mphahlele, COVID-19 vaccine: the challenges of running a
trial in the middle of a pandemic, THE CONVERSATION (July 7, 2020),
https://theconversation.com/covid-19-vaccine-the-challenges-of-running-a-trial-in-themiddle-of-a-pandemic-141728.
53 Samiran Nundy et al., A New Colonialism? -- Conducting Clinical Trials in India, 352 NEW
ENG. J. OF MED. 1633, 1634-6 (2005).
54 Wemos Foundation, The Clinical Trials Industry in South Africa: Ethics Rules and Realities
(Amsterdam:
Wemos
Found.,
July
2013),
https://www.wemos.nl/wpcontent/uploads/2016/06/Clinical_Trials_Industry_South_Africa_2013.pdf.
55 C. Lee Ventola, Progress in Nanomedicine: Approved and Investigational Nanodrugs, 42
PHARMACY & THERAPEUTICS 742, 744 (2017).
56 Sirolimus is a target of the rapamycin inhibitor with immunosuppressive properties. Its
clinical application is limited due to its poor solubility. The FDA approved the nanoformulation of the drug and is marketed as RapamuneÒ.
57 Doxorubicin is an anti-cancer drug that is widely used for the treatment of numerous tumors,
including breast, ovarian, and lung. However, due to its irreversible cardiotoxicity a liposomal
shell was designed to protect the untreated tissue and organs from its toxicity. The FDAapproved liposomal Doxorubicin products are DoxilÒ, LipodoxÒ, and MyocetÒ.
58Available
at:
https://www.grandviewresearch.com/industry-analysis/liposomaldoxorubicin-market.
59 See https://clinicaltrials.gov/ (enter “Doxil” into “Other terms” search box; choose “Saudi
Arabia” from “Country” dropdown; then click “Search” button).
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organization), public and private hospitals, as well as healthcare providers.
The legal obligation/liability towards volunteers of a clinical trial depends
on the role of these actors and their interaction with volunteers. Regulatory
agencies, as agents of states, are required to ensure adequate protection. To
shield the individuals and entities implementing crisis measures from
targeted liability, authorized emergency measures need to be instituted. For
example, the US Federal Public Readiness and Emergency Preparedness
(PREP) Act60 protects entities that implement health countermeasures
approved for emergency use by the FDA from liability. The PREP Act
provides limited tort liability protections, among others, to vaccine
manufacturers, pharmacists, and medical professionals. A compensation
fund is established for injured volunteers. The immunity provided by the
PREP Act, however, is limited and faced legal challenges on the basis of
inadequate informed consent.61
The US Food and Drug Administration (FDA) issued guidance to assist
clinical trial sponsors assuring the safety of the trial volunteers, maintaining
compliance with good clinical practice, and minimizing the risks to the
integrity of clinical trials during the pandemic.62 The FDA deviated from the
required public notice63 and allowed for the guidance to be applied
immediately. However, the FDA made it clear that the guidance is not
establishing a set of legally binding responsibilities. This is a major deviation
from the normal practice of FDA,64 which restrict waving or the appearance
of waving of any legal right against the investigator or the sponsor of a
clinical trial.65
Claims may be advanced at the producer’s home state, or place of
headquarters, as was the case with suits against the producers of the Torvan
drug,66 even though the clinical trial in question (from which the suit arose)

60 42

U.S.C. § 247d-6d (2020).
Parker v. St. Lawrence County Pub. Health Dept., 102 A.D.3d 140 (2012).
62 FDA, Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health
Emergency (2021), https://www.fda.gov/media/136238/download.
63 According to the FDA regulations, a public notice is required pursuant to 701(h)(1)(C)(i)
of the FDA Act and 21 CFR 10.115(g)(2). When public participation is not feasible, the Act
could be implemented without notice or comment period.
64 See A Risk-Based Approach to Monitoring of Clinical Investigations Questions and Answers
Guidance for Industry, https://www.regulations.gov/document?D=FDA-2019-D-0362-0002
65 See 46 FR 8951, Jan. 27, 1981, as amended at 64 FR 10942, Mar. 8, 1999.
66 Trovan is a drug produced by Pfizer, which was found to result in long-term brain damage
and death for some of the participants. See Harpreet K. Pannu, Acute Liver Failure due to
Trovafloxacin: CT Findings, 8 EMERGENCY RADIOLOGY 108 (2001); Joe Stephens, Pfizer to
Pay USD 75 Million to Settle Nigerian Trovan Drug-Testing Suit, THE WASHINGTON POST,
July 31, 2009.
61
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was conducted in Nigeria.67 That courts in developed states apply (or not)
the forum non conveniens principle in order to assert jurisdiction over
conduct committed in the (outsourced) country where a clinical trial took
place, is an integral part of the notion that multinational corporations
(MNCs) are responsible for their direct impact on people and communities
in their countries of operation,68 so long as they had a directing role in the
conduct in question.69This is usually difficult to ascertain and prove.
The administration of nano-enabled drugs is governed by policies and
laws specific to the jurisdiction in which the clinical trials are performed.
Informed consent obligations conferred on the investigator in a clinical trial
are well entrenched.70 However, there is no internationally recognized risk
governance framework for informed consent whereby participants can
critically review and agree to its terms ahead of volunteering to the treatment.
Jurisdictions that are not fully equipped with sufficient scientific know-how
concerning the formulation of vaccines enabled with nano-carriers lack the
expertise to assess the risks associated with the complexity, uncertainty and
ambiguous nature arising from the administration of mRNA vaccines and its
nano-carriers. Further, there is no international regulatory framework for
admitting nano-enabled drugs or vaccines to the clinical trial markets.
The outsourcing of clinical trials in developing countries has led to a
string of cases where volunteers questioned the propriety of informed
consent. In a case heard in Argentina, the judge rejected GlaxoSmithKline’s
defense that complying with informed consent requirements was a mere
formality, the absence of which did not pose an actual risk to the volunteer
participants. The court went on to explain that: “even minor deficiencies in
the procedure could become relevant later on as certain health effects may

67 Abdullahi

v. Pfizer, Inc. 562 F.3d 163 (2d Cir. 2009).

68 See e.g. Chandler v Cape PLC [2012] EWC. Civ 525; See also

Landgericht Dortmund weist
Klage gegen KIK wegen Verjährung [Jabir v KiK Textilen und Non-Food GmbH 7 O 95/15
decision
of
10
January
2019],
available
at: http://www.lgdortmund.nrw.de/behoerde/presse/Pressemitteilungen/PM-Urteil-KIK.pdf . See Vivian G.
Curran, Harmonizing Multinational Parent Company Liability for Foreign Subsidiary Human
Rights Violations, 17 CHI. J. OF INT’L L. 403 (2016).
69 See Okpabi and others v Royal Dutch Shell Plc (2018) EWCA Civ 191 and as approved by
the UK Supreme Court. The Court of Appeal effectively denied jurisdiction over claims by
victims oil spills in the Niger Delta. Okpabi is somewhat in contrast to Lungowe and Others
v Vedanta Resources Plc [2017] EWCA Civ 1528 where the Court of Appeal delivered had
held a year earlier that environmental tort claims, such as those raised in Okpabi, could
proceed in English courts, arguing that the UK parent company owed a duty of care to the
overseas claimant.
70Stacey B. Lee, Informed Consent: Enforcing Pharmaceutical Companies' Obligations
Abroad, 12 NATL. LIBR. OF MED. 15 (2010).
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only occur in the future.”71 That drug manufacturers, whether sponsoring
international clinical trials or not, have legal obligations arising from such
processes has been made abundantly clear. The Indian Supreme Court
reasoned that manufacturers have a duty of care towards clinical trial
volunteers in accordance with the Caparo test of foreseeability, proximity
and fairness.72
One of the legal side effects of transnational clinical trial outsourcing is
the presumption that informed consent is at best a non-conducive (i.e. not an
essential condition for the volunteer/offeree) contractual term, or a tort,
assuming that some harm occurs. In the first case the breach of contract
arising from the absence of appropriate informed consent does not lead to
significant damages and is not a cause for the termination of contract. On the
other hand, tort-based liability will arise where local laws require a duty of
care (i.e. concerning informed consent) and harm is caused to the participant.
It is clear that both contractual and tort-based mechanisms, although useful,
should only be used residually and not as the primary source of obligations
by drug manufacturers.
At present, most clinical trials on novel COVID-19 vaccines are
domesticated in the home state where the vaccine is being developed. The
most successful reported vaccine efficacy tests concern the two vaccines by
ModernaTX and Pfizer. The ModernaTX vaccine Phase 3 clinical trial was
administered on 30,000 participants at 100 different locations in the United
States.73 Pfizer tested its vaccine on over 40,000 trial participants.74 Johnson
and Johnson announced its Phase 3 transboundary clinical trial for its
COVID vaccine to include 60,000 participants in Argentina, Brazil, Chile,
Colombia, Mexico, Peru, South Africa and the United States.75 In the case of
the EU alone, volunteers may be subject to vaccination treatment with a
product that is not available in the market of a member State, which
71 Andrea

Gerlin, Glaxo to Appeal Fines in Argentina Case Over Synflorix Trial, BLOOMBERG
BUSINESSWEEK (Jan. 3, 2012), https://www.bloomberg.com/news/articles/2012-01-03/glaxoto-appeal-fines-in-argentina-case-over-synflorix-trial.
72 Karine Morin, The Standard of Disclosure in Human Subject Experimentation, 19 J. OF
LEGAL MED. 157 (1998).
73 ‘Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis
of
SARS-CoV-2
Infection
(COVID-19)’
available
at:
https://clinicaltrials.gov/ct2/show/NCT04283461
74 ‘Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine
Candidates
Against
COVID-19
in
Healthy
Individuals’,
available
at:
https://clinicaltrials.gov/ct2/show/NCT04368728.
75
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19
Vaccine Candidate, Johnson & Johnson (Sept. 23, 2020), https://www.jnj.com/johnsonjohnson-initiates-pivotal-global-phase-3-clinical-trial-of-janssens-covid-19-vaccinecandidate.
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nonetheless has been authorized in another member State ‘where it is not
possible to treat a disease with medicinal products available in the country’.76
In all other circumstances, however, States should have accrued State
obligations for the protection of the right to health, both extra-territorially
and vis a vis private corporations.
A surge in the number of transnational clinical trials for nano-enabled
vaccine carriers is anticipated. At present, a sizeable number of clinical trials
are running to evaluate the efficacy of nano-enabled drug carriers.77
International clinical trials of nano-enabled drugs may provide a benefit to
volunteers and governments in the developing world, as nano-enabled drugs
provide access to medical treatment that is otherwise unavailable; At the
same time, it saves costs for producers. The cost of clinical trials in
developed countries is almost 90 per cent cheaper than in developing
countries.78 However, the delegation to third parties to conduct such trials
does not release the manufacturer from its own liability.79 International
medical professional organizations80 require that informed consent be
properly obtained, and adequate monitoring systems be implemented for all
clinical trials.
Speedy clinical trials pose additional complexities with regard to
receiving adequate information and monitoring the results. In many cases,
volunteers are either denied crucial information about the phase of testing,
the dangers associated with the particular drug, or the available data relating
to the financial needs and expectations of the volunteer. In October 2020, for
example, the NY Times reported that US-based Eli Lilly and the National
Institutes of Health were among the first to conduct clinical trials with
COMM. FROM THE COMM’N TO THE EURO. PARL., THE EURO. COUNCIL, THE COUNCIL AND THE
EURO. INVEST. BANK: EU Strategy for COVID-19 VACCINES, COM/2020/245 final (Jun 17,
2020)
(available
at
https://eur-lex.europa.eu/legalcontent/EN/TXT/?uri=CELEX%3A52020DC0245).
77 See www.clinicaltrials.gov (search with keyword “nano”) (showing that as of December
30, 2020, there were 345 studies of nano-enabled products being experimented in 101 trials
in Europe, 83 in the US, 35 in the Middle East, 29 in East Asia, 27 in Africa, 14 in South
America, 9 in Australia, 13 in Canada, 3 in Japan, 5 in Russia, 2 in India and 2 in Mexico).
78 Joanne Nicholas, Outsourcing Clinical Trials, 104 J. OF THE NAT’L CANCER INST. 1043
(2012).
79 See 21 CFR 50.20 (emphasizing that “No informed consent, whether oral or written, may
include any exculpatory language through which the subject or the representative is made to
waive or appear to waive any of the subject's legal rights, or releases or appears to release the
investigator, the sponsor, the institution, or its agents from liability for negligence.”).
80 See, e.g., the EC Commission Directive 2005/28/EC of 8 April 2005 (laying down
principles and detailed guidelines for good clinical practice for investigational medicinal
products for human use, as well as the requirements for authorisation of the manufacturing or
importation of such products).
76
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monoclonal antibodies in nursing homes. 81 Many of the residents in these
homes “have dementia, or have difficulty seeing and hearing.”82 Therefore,
trial managers are obliged to properly obtain informed consent from
volunteers, which itself may be traced as far back as Article I of the
Nuremberg Code: “The duty and responsibility for ascertaining the quality
of the consent rests upon each individual who initiates, directs or engages in
the experiment. It is a personal duty and responsibility which may not be
delegated to another with impunity.”83

IV. HUMAN RIGHTS VIOLATIONS BY STATES AND NON-STATE
ACTORS DURING THE COVID-19 PANDEMIC
What remains to be examined, therefore, is whether the emergence of
the pandemic is a factor that influences human rights obligations of States.
In other words, the question is whether the dilution of obligations related to
seeking informed consent is justified due to the application of a special
regime during the pandemic.
This is hardly the first pandemic in recent history. The International
Sanitary Convention,84 which initially dealt only with cholera, was adopted
in 1892, following the Cholera Epidemic of 1873. These conventions
followed worldwide efforts towards international health cooperation,
beginning with the first International Sanitary Conference in Paris, which
opened on 23 July 1851, and followed by another Convention dealing with
the plague in 1897. 85 Their objective was to “harmonize and reduce to a safe
Gina Kolata, An ‘Unprecedented’ Effort to Stop the Coronavirus in Nursing Homes, N.Y.
TIMES (Aug. 20, 2020), https://www.nytimes.com/2020/08/20/health/coronavirus-nursinghomes.html.
82 Id.
8311 TRIALS OF WAR CRIMINALS BEFORE THE NUREMBERG MILITARY TRIBUNALS UNDER
CONTROL
COUNCIL
LAW
NO.
10,
181-182
(1949)
(available
at
https://www.loc.gov/rr/frd/Military_Law/pdf/NT_war-criminals_Vol-II.pdf) (noting that the
Nuremberg Code resulted from Trials of War Criminals before Nuremberg Military Tribunals
under Control Council Law No 10: Nuremberg, October 1946-April 1949, in which Nazi
doctors were put on trial for experimenting on humans in concentration camps. The Code
establishes principles for human subject research protection).
84 International Sanitary Convention, PAN AMERICAN HEALTH ORGANIZATION (1892),
https://www.paho.org/hq/index.php?option=com_content&view=article&id=13878:ivinternational-sanitary-convention&Itemid=2261&lang=en.
81

85

Lawrence O. Gostin, World Health Law: Toward a New Conception of Global Health
Governance for the 21st Century, 3 YALE J. HEALTH, POL. & ETHICS 413, 414 (2005) (also
giving an account of instruments pre-dating the Charter) (noting that in 1903, the International
Sanitary Convention replaced the conventions of 1892 and 1897).
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minimum the conflicting and costly maritime quarantine requirements of
different European nations.”86 The effectiveness of these treaties, however,
has been limited, aiming at international cooperation rather than the
establishment of a special regime. As a result, the legal regime applicable in
situations of pandemics, akin to disasters, remains the regime of derogations.
A. BRIEF OVERVIEW OF THE GENERAL DEROGATION REGIME UNDER
THE ICCPR
The right to declare a State in a situation of emergency and subsequently
take derogatory measures from some human rights obligations is a right that
States possess. The ICCPR, the primary instrument guaranteeing rights that
are traditionally perceived as “civil and political,” allows derogations in
exceptional circumstances. Such circumstances have been defined as a “time
of public emergency which threatens the life of the nation, the existence of
which is officially proclaimed” under article 4.87 This provision is central to
the exercise of sovereign power, subsequent to executive orders and other
types of extraordinary powers of the executive. “When the State is engaged
in a life and death struggle, no one can demand that it refrain from taking
special emergency measures: salus rei publicae suprema lex est”.88
The first safeguard to of the article, is the second paragraph of article 4,
which stipulates that some rights can never be derogated from, even in such
times of emergency that threaten the life of a nation, as is the case with an
epidemic – or pandemic. This list of rights is not subject to derogations.89

Global Health Histories, Origin and development of health cooperation, WHO,
https://www.who.int/global_health_histories/background/en/ (explaining history of the
conventions).
87 Art 4 para 1 and 4 para 2. In time of public emergency which threatens the life of the nation
and the existence of which is officially proclaimed, the States Parties to the present Covenant
may take measures derogating from their obligations under the present Covenant to the extent
strictly required by the exigencies of the situation, provided that such measures are not
inconsistent with their other obligations under international law and do not involve
discrimination solely on the ground of race, colour, sex, language, religion or social origin.
See generally, D McGoldrick, The Interface Between Public Emergency Powers and
International Law, 2 INT’L J. CONST. L. 380, 383 (2004).
88 Lawless v. Ireland (1961), 1 EHRR 15 (the case concerned an IRA suspect detained under
emergency legislation).
89 See Dominic McGoldrick, The Interface Between Public Emergency Powers and
International Law, 2 INT’L J. CONST. L. at 383 (2004) (“No derogation from articles 6, 7, 8
(paragraphs I and 2), 11, 15, 16 and 18 [religious freedom] may be made under this
provision”).
86
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This list has been extensively discussed during the drafting of the ICCPR. 90
The Committee has stated several times that States cannot evade the
obligations which they have undertaken by ratifying the Covenant.”91
Under human rights law, several important safeguards apply.92 First,
such powers may be applied in exceptional circumstances only, like when
the ‘life of a nation’ is threatened. If no such circumstance is present, the
normal legal regime applies. Second, the right to take such measures is
subject to notification requirements. This notification has the purpose of
making the situation public and may take the form of a formal declaration to
the relevant body – namely, the Secretary General of the United Nations (UN
SG) or of the OAS – in the case of the ACHR.93
In some cases, therefore, as under the ECHR, emergency measures
taken by States may not be lawful for the only reason that the pertinent
notification requirement was not met.94 The same applies in the context of
the OAS and under the ACHR, which requires in addition that notification
of derogations be made “immediately.”95 Third, it can only apply for a
Marc Bossuyt, Guide to the "travaux Préparatoires" of the International Covenant on Civil
and Political Rights (Martimus Nijhoff 1997) at 91ff; UN Human Rights Committee (HRC),
CCPR General Comment No. 29: Article 4: Derogations during a State of Emergency, 31
August 2001, CCPR/C/21/Rev.1/Add.11, para 9 in fine. In the adopted version of the ICCPR
non- derogable rights include fundamental civil rights such as the right to life, freedom from
torture, freedom from slavery and curiously also religious freedom. In relation to religious
freedom (which is clearly derogable under other instruments, such as the ECHR for example),
most States, seemed to agree that even if religious freedom under 18 is non- derogable, this
is not the case also with article 18 paragraph 3 in relation to the manifestation of a religion.
This means therefore that States have the right to close down places of warship, yet these
limitations should be only as a measure of last resort, and only if this does not fully deny
religious freedom. This point is also made by the HRC which highlights that ‘even in times
of most serious public emergencies, States that interfere with the freedom to manifest one’s
religion or belief must justify their actions by referring to the requirements specified in article
18, paragraph3’.
91 McGoldrick, The Interface Between Public Emergency Powers and International Law, 2
INT’L J. CONST. L. at 390 (2004).
92 Id. at 383 (defining derogations as “complete or partial elimination as an international
obligation.”).
93 Constitutional Rights Project, Civil Liberties Organisation and Media Rights Agenda
(1994), (“[T]he African Charter does not contain a derogation clause. Therefore, the
limitations on the rights and freedoms enshrined in the Charter cannot be justified by
emergencies and special circumstances. The only legitimate reasons for limitations to the
rights and freedoms of the Charter are found in article 27(2).”).
94 The European Commission for instance has found that derogations are not valid in the
absence of notification, as the situation has not become officially public. See on Greece v. UK,
ECHR Commission report, para 158; Cyprus v. Turkey, Commission report of 4 October 1983
para 68; Silva v. Uruguay, Communication No. R.8/34, U.N. Doc. Supp. No. 40 (A/36/40) at
130 (1981).
95 McGoldrick, supra note 90.
90
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limited period time and for limited rights only. Most international human
rights instruments provide such specific conditions for the lawfulness of such
”derogations”, while at the same time set out a minimum ensemble of rights
that can be never derogated from irrespective of circumstances. Human
rights bodies, subsequently, have had the opportunity to elaborate on the
legality of such derogations’ regimes – which have indeed in the past been
subject to abuse.
B. APPLICABILITY OF THE DEROGATION REGIME DURING PANDEMICS
SUCH AS COVID-19
Most states have instituted extreme quarantine measures and declared a
state of emergency.96 As of December 2020, according to the latest version
of statistics by the WHO, there were globally over 75 million confirmed
cases and over 1.6 million deaths (about 2.2 per cent), with numbers rising
worldwide.97 This prompted many countries to declare themselves in a state
of public health emergency. In response, states adopted measures heavily
restricting fundamental rights and freedoms such as freedom of movement.
Restrictions have been less in line with the numbers of infections, and rate
of mortality (see Fig.1), and more the product of political choices.98
Undoubtedly, the pandemic has exemplified the huge gap between
developed and safe countries as well as between developing and fragile
countries,99 in the same way that it has exemplified the divide between rich
and poor or low-income families.100
96

Eg., the U.S. declared a national emergency concerning the coronavirus on March 13, 2020.
https://www.ncsl.org/ncsl-in-dc/publications-and-resources/president-trump-declares-stateof-emergency-for-covid-19.aspx.
97
WHO, Weekly epidemiological update-15 (Dec. 20, 2020) available at:
https://www.who.int/publications/m/item/weekly-epidemiological-update-15-december2020.
98 See e.g., Manuela Andreoni, Coronavirus in Brazil: What You Need to Know,
https://www.nytimes.com/article/brazil-coronavirus-cases.html.
99 Yemen and Vietnam’s death rates are among the highest worldwide (29 people die for every
100 reported infection cases in Yemen). See Weekly Epidemiological Update, WORLD HEALTH
ORG. (Dec.15, 2020), https://www.who.int/publications/m/item/weekly-epidemiologicalupdate---15-december-2020. Only Vietnam was able to adopt effective measures. See, e.g.,
Anna Jones, Coronavirus: How 'overreaction' made Vietnam a virus success, BBC NEWS (15
May 2020), https://www.bbc.com/news/world-asia-52628283. On Yemen on the contrary, see
Coronavirus
Data:
Yemen
Situation,
WORLD
HEALTH
ORG.,
https://covid19.who.int/region/emro/country/ye (last updated Feb. 8, 2021).
100
Derek Thompson, The Coronavirus Will Be a Catastrophe for the Poor, THE ATLANTIC
(Mar. 20, 2020), https://www.theatlantic.com/ideas/archive/2020/03/coronavirus-willsupercharge-american-inequality/608419/.
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The first rights that are typically suspended in a pandemic, such as the
Covid-19 outbreak, would be Article 12 (right to liberty of movement),
Article 19 (right to freedom of expression) and Article 21 (right of peaceful
assembly) of the ICCPR. 101 The Human Rights Committee has specifically
underlined that “not every disturbance or catastrophe qualifies as a public
emergency which threatens the life of the nation, as required by Article 4,
paragraph 1”. This is the case of both national and international armed
conflict, for instance – whereby human rights may still be applicable even
though humanitarian law applies as lex specialis.102 In relation to other
situations, not covered by the definition of an armed conflict (as in an
epidemic, or a fortiori a pandemic), the Human Rights Committee does not
warrant unlimited power to States in relation to derogable rights. On the
contrary, under the Covenant, any measures derogating from a State party’s
obligations must be limited “to the extent strictly required by the exigencies
of the situation.”103
The HRC, in addition, highlights that “if States parties consider invoking
Article 4 in situations other than armed conflict, they should carefully
consider the justification and why such a measure is necessary and legitimate
in the circumstances” and that “on a number of occasions, the Committee
has expressed its concern over States’ parties that appear to have derogated
from rights protected by the Covenant, or whose domestic law appears to
allow such derogation in situations not covered by Article 4”.104 This means
that States do not have unlimited powers to impose exceptional regimes of
unlimited derogations, even in relation to non-derogable rights. On the
contrary, derogations are subject to necessity and proportionality
requirements, whereby necessity’ should be defined as a measure of last
resort. According to the Committee, geographical coverage, duration, and
material scope of the state of emergency are the main requirements in
defining both necessity and proportionality. 105 Travel bans, for example,
should not exceed the duration that is absolutely necessary to fight the
diffusion of a pandemic (and inversely, that the geographical coverage of the
Cf. analytically, Alessandra Spadaro, COVID-19: Testing the Limits of Human Rights, 11
EUR. J. OF RISK REG. 317, 320–21 (2020).
102 U.N. Human Rights Comm., General Comment No. 29: State of Emergency (Art. 4) para
3, CCPR/C/21/Rev.1/Add.11 (July 24, 2001). This comment is an improvement of previous
General Comment no 5. See Sarah Joseph, Human Rights Committee General Comment No.
29, 2 HUM. RIGHTS L. REV. 81 (2002).
103
UN HRC, supra note 100, para 5.
104 Id. at para 3.
105 Id. at para 4.
101
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measures taken should follow the rhythm of spread of a pandemic and should
not be as strict as in the epicenter or its surroundings). It also follows
logically that necessity and proportionality are the necessary requirements in
the actions of those ensuring compliance with quarantine measures such as
national police authorities, armed forces and the military and immigration
authorities.
In addition, the Committee specifically highlights that even though some
articles have been listed as non-derogable, States have “a duty to conduct a
careful analysis under each article of the Covenant based on an objective
assessment of the actual situation.”106 These findings are extremely pertinent
in pandemics, whereby States may typically derogate without carefully
balancing the interests at stake. Hence, rights commonly derogated from
pandemics, as in Covid 19, are typically the liberty of movement and
freedom to choose one’s residence (article 12 para 1); the right to leave or
enter one’s own country under article 12, para 2, and 12 para 4; and the ‘right
to liberty and security of person’, and the right to private and family life
(Article 17), in case of separation of family members in view of confining
individuals affected. This means, for instance, that separation of families
may be, at its face, a violation of Article 17 and the right not to interfere with
one’s privacy and family life unlawfully, especially if home-confinement is
an alternative. The same applies to prisoners – solitary confinement or
visitations and restrictions to prisoners107 are, in principle, in breach of
Article 17 of the ICCPR.
State practice in relation to derogations in relation to epidemics until now
has been rather scarce. It is arguably the first time that States notify the UN
SG that they will be imposing a regime of derogations from their human
rights obligations under the ICCPR. The same has happened with
derogations under the ECHR. To date, the UN SG has received 12
notifications under Article 4 of the ICCPR. 108 Guatemala has issued four
notifications from February 19 to March 31, 2020. Guatemala is, in fact, one
of the States that have made maximum use of this procedure. Guatemala used
this procedure in 2010 to notify the SG about derogations due to natural
disasters such as Hurricane Mitchand Hurricane Stan in 2005, as well as in
relation to the eruption of the Pacaya volcano in 2010, to the devastations
caused by tropical storm Agatha, and because of a 7.8 (on the Richter scale)
Id. at para 6.
Barr and Christina Carrega, State prisons prepare for coronavirus but federal prisons
not providing significant guidance, sources say, ABC NEWS (Mar. 11, 2020, 12:42 PM),
https://abcnews.go.com/US/state-prisons-prepare-coronavirus-federal-prisons-providingsignificant/story?id=69433690.
108 Notifications under Article 4 of the ICCPR, UNITED NATIONS TREATY CTR.,
https://treaties.un.org/Pages/CNs.aspx?cnTab=tab2&clang=_en.
106

107Luke

170

HASTINGS SCIENCE AND TECHNOLOGY LAW JOURNAL

Vol. 12:2

earthquake in 2012.109 Likewise, in 2009, Guatemala deposited a derogation
in light of the ‘swine flu’ pandemic. On that occasion, a ‘public health
emergency’ was declared throughout the national territory for a period of
thirty days. The 2009 swine flu pandemic or swine flu was an influenza
pandemic that lasted from January 2009 to August 2010.110
The most recent notification is that dated 20 March by Peru, which has
imposed extensive quarantine orders due to the COVID 19 health
emergency, resulting in ‘total closure of borders, suspending therefore
international passenger transport’ under an emergency degree dated 20
March 2020, which imposed necessary confinement at home from 8.00 p.m.
to 5.00 a.m. and compulsory isolation for those who travelled the days prior
to the issuance of the degree. Hence Peru notified that it will be suspending
articles 9, 17, 21 and 12 of the ICCPR, allowing individuals [to] move around
only to provide and avail themselves of the food products, pharmaceuticals
and staple goods and in order to attend health centers and to perform their
work.111 The only services allowed by the authorities are those ‘ensur[ing]
water, sanitation, electricity, gas, fuel, communications, solid waste
collection and funeral services’ and ‘assistance and care for elderly persons,
children, adolescents, dependents, persons with disabilities or vulnerable
persons’; ‘financial, insurance and pension entities, as well as
complementary and related services that ensure their proper functioning’;
‘production, storage, transport, distribution and sale of fuel’ hotels and other
facilities providing accommodation, only for the purpose of complying with
the quarantine order; ‘media and telephone call centers’; and public sector
workers who, exceptionally, provide services.
In all situations, non-discrimination and human dignity should be the
yardsticks. This may happen in a scenario arising from obligatory placement
in confinement centers to stop spreading of a disease as in the case of
pandemics. Conditions in such centers should be consistent with minimum
dignity standards. In this respect, freedom from cruel, inhuman or degrading
treatment or punishment, including also the right to be free from ‘medical or
scientific experimentation without one’s free consent’ is part of nonderogable contents of article 6. Likewise, the right to privacy may also be
especially susceptible to abuses in case States pass new laws warranting
compulsory testing and the automatic identification of former COVID-19
109See

Emanuele Sommario, Limitation and Derogation Provisions in International Human
Rights Law Treaties and their Use in Disaster Settings, in ROUTLEDGE HANDBOOK OF HUMAN
RIGHTS AND DISASTERS 21(Flava Zorzi Giustiniani et al. eds., 2018).
110
Id.
111 C.N.123.2020. TREATIES-IV.4 (Depositary Notification), ICCPR notification under 4 (3),
Peru, dated 20 March 2020.
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patients by the authorities on the basis of the so-called digitized ‘immunity
passports’, as suggested by the UK and US.112 Such identification may have
an impact of privacy and increase stigmatization, and ultimately,
discrimination – especially in the case of young individuals and in relation
to the right to work.
C. DEROGATIONS FROM THE RIGHT TO HEALTH DURING THE COVID19 PANDEMIC?
Social and economic rights are also affected during the pandemic,
especially the right to health and the right to a healthy environment. The
interrelation between types of rights necessarily encompasses the
preservation of the right to health through limitation of other rights – such as
the right to personal freedom, or freedom of movement.113 Contrary to the
ICCCPR, however, the ICESCR does not contain a comprehensive provision
on derogations. It only contains a provision on possible limitations ‘solely
for the purpose of promoting general welfare in a democratic society’ and
insofar as ‘this may be compatible with the nature of these rights’ (article 4).
It is also explicitly stated in the ICCPR that ‘no restriction upon or derogation
from any of the fundamental human rights recognized or existing in any
country in virtue of law, conventions, regulations or custom shall be admitted
on the pretext that the present Covenant does not recognize such rights or
that it recognizes them to a lesser extent’ (article 5).
In reality, the legitimacy of derogations to economic, social and cultural
(ESC) rights cannot be easily distinguished from the exact scope of these
rights and subsequent obligations. 114 The reason is that ESC rights are
intrinsically related to the management of scarce resources.115 This entails
COVID-19 Information, U.S. EMBASSY & CONSULATES IN THE UNITED KINGDOM, (Jan. 27,
2021, 3:00 PM), https://travel.state.gov/content/travel/en/traveladvisories/ea/passport-covid19.html.
113 Spadaro, supra note 99, at 319 (noting that ‘public health measures consisting in the
112

enforcement of social distancing, which are deemed effective in reducing the spread of certain
influenza-like diseases, including COVID-19, clash with a number of individual rights. It is
worth giving a few examples, based on some of the most commonly adopted measures, with
no pretence of providing an exhaustive overview’).
114 Amrei Müller, Limitations to and Derogations from Economic, Social and Cultural Rights,
HUM. RTS. L. REV. (2009) 9(4): 557, 558 (arguing that the legitimacy of derogations to
economic, social and cultural (ESC) rights cannot be easily distinguished from the exact scope
of these rights and subsequent obligations).
115 U.N. Human Rights, Office of the High Commissioner, International Covenant on
Economic, Social and Cultural Rights, Art 2.1, (”Each state party to the present Covenant
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the adaptation of public health strategies, such as the mean non-denial of
materials that are vital for non-contamination, such as soap and sanitizers,
especially to the most vulnerable and needy. Those should continue being
available, accessible and affordable at all times,116 even if this means for the
State dispensing additional resources. In cases of pandemics, violations
against the right to health may, therefore, include denial of treatment due to
conflicting obligations in treating patients who are more in need; or even
denial of basic healthcare material for specific groups of the population,
especially when States find that this may have adverse circumstances, such
as, for instance, refusing or not providing hand sanitizers in prisons for fear
of intoxication.117
The non-discrimination principle seems to be again the guideline in
relation to socio-economic rights,118 especially in relation to vulnerable
segments of the population. Sacrifice of one’s life over another will
unavoidably take place in pandemic scenarios, where tough choices will
need to be made. Most States in Covid-19 management have been
prioritizing treatment of children and youths with underlying conditions, for
instance, over the elderly, and this is something that most people find morally
justified. While it may be possible to prioritize certain groups in need, nondiscrimination entails that other segments of the population cannot
consistently and persistently be excluded from access to healthcare,
medicine and treatment. This does not apply only to the elderly, but also to
persons with disabilities, health workers, human rights activists and other
people with needs. In the event of increased risk of infection, increased rather
than core obligations119 should be applicable to those residing in refugee
camps and shelters, homeless persons or undocumented migrants, those
confined in prisons and also those found in battlefields and in situations of
armed conflict during the outbreak of the pandemic, both combatants and
civilians. In such cases, humanitarian law and primarily the obligation to
provide humanitarian aid applies in parallel to the international human rights
regime, similar to the international disaster framework.120

undertakes to take steps, individually and through international assistance and co-operation,
especially economic and technical, to the maximum of its available resources, with a view to
achieving progressively the full realisation of the rights recognised in the present Covenant
by all appropriate means, including particularly the adoption of legislative measures”).
116 Id.
117 UN Commission on Human Rights, Limburg Principles on the Implementation of the
ICESCR 8 January 1987, E/CN.4/1987/17.
118
International Covenant on Economic, Social and Cultural Rights, supra note 113.
119 Limburg Principles, supra note 115.
120 Sommario, supra note 107.
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D. PHARMACEUTICAL COMPANIES’ OBLIGATIONS DURING THE COVID19 PANDEMIC
The obligation to seek trial participants’ informed consent as well as the
obligation to protect personal data under human rights law are both tackled
under the right to privacy, which ‘protects individuals against arbitrary
interference by public authorities’.121 As discussed in the previous section,
during pandemics, States are obliged to conform to necessity and
proportionality requirements to protect this right, even during pandemics. In
reality, however, the question is more complex, since typically testing is
done by pharmaceutical companies – i.e. private actors – rather than state
authorities. Two aspects of pharmaceutical companies’ duties will be
discussed in this section, first, the duty to seek clinical trial participants’
informed consent in relation to all possible risks, and secondly, the obligation
to protect trial participants’ personal data.
i. Clinical Trial Participants’ Informed Consent
Pharmaceutical companies and corporations are not exempt from the
obligation to conform with human rights law and from seeking trial
participants’ informed consent, especially when conducting clinical trials
abroad. The interpretation of human rights standards by international and
regional bodies has expanded to encompass States obligations to regulate
private actors. General Comment 14 of the CESCR in particular indirectly
links the right to health with healthcare services provided by private
corporations, which typically arise in situations where the State has
outsourced part of its healthcare obligations to private providers.122 This
means that both the manufacturer and the host State are under strict
obligations to conduct clinical trials in a manner that is human rightscompliant and in addition States must regulate such activities under sanction
of law.
Pharmaceutical companies’ duties have arisen primarily in relation to
access to medicine and intellectual property rights. More recently, however,
UN bodies and particularly the UN Special Rapporteur on the right to the
highest attainable standard of health have been referring gradually also to
clinical trials. According to the UN GA guidelines for Pharmaceutical
companies (2008) ‘a company’s clinical trials should observe the highest
ethical and human rights standards, including non-discrimination, equality
and the requirements of informed consent’, a requirement that is ‘especially
121 Solomakhin,

supra note 39.
Human Rights Committee, General Comment No.14: The Right to the Highest Attainable
Standard of Health (Art. 12), at ¶36, Aug. 11, 2020.
122

174

HASTINGS SCIENCE AND TECHNOLOGY LAW JOURNAL

Vol. 12:2

vital in those States with weak regulatory frameworks.123 According to the
guidelines, these companies should equally conform to medical ethics, in
particular ‘to the Declaration of Helsinki on Ethical Principles for Medical
Research Involving Human Subjects, as well as the World Health
Organisation Guidelines for Good Clinical Practice’.124 Also, in its guiding
principles on corporate responsibility, the OHCHR notes that
‘pharmaceutical companies should be able to communicate how they ensure
that drug trials are conducted safely and with adequate information and
consent’.125 Individuals, therefore, should have the right to challenge
strategies by pharmaceutical companies and corporations that are not in
conformity with these standards. In its “General Comment on the nature of
State obligations”, the Human Rights Committee emphasizes the
significance of providing effective remedies against any perpetrator of
human rights violations.126
Assuming that the pandemic constitutes a national emergency, and that
the derogations regime is applicable, the prescription drug developer owes a
duty of care to disclose all known and anticipated risks to participants. The
duty of care cannot be diminished due to the emergency. Since the regulatory
authority probably reduces its “oversight”, the duty on the developer, as the
foremost expert on the potential risks, increases. For example, the FDA
allowed in its guidance of clinical trials during Covid-19 for the sponsor to
have the flexibility to adjust the protocol of clinical trials depending on the
specific circumstances and by consultation with the Institutional Review
Board (IRB).127 Allowing for the IRB review to substitute the FDA review
is a substantial change under the crisis condition that would not have been
permitted under normal circumstances. The guidance allowed for alternative
methods for safety assessment that are consistent with the clinical trial
protocol “to the extent possible.” Consultation with the FDA is
recommended but not mandatory.128 The FDA through a high level of
flexibility is shifting the burden to the sponsor of clinical trials.

U.N. GAOR, H UMAN RIGHTS G UIDELINES FOR PHARM. COS. IN RELATION TO ACCESS TO
MEDS. 21 (A/63/263, 2008).
124 Id. at 22.
125 U.N HUMAN RTS., OFF. OF THE HIGH COMM’R, THE CORP. RESP. TO RESPECT HUMAN RTS.
58 (2012).
126 U.N HUMAN RTS., OFF. OF THE HIGH COMM’R, THE CORP. RESP. TO RESPECT HUMAN RTS.
58 (2012).
127
See FDA, CONDUCT OF CLINICAL TRIALS OF MED. PRODUCTS DURING THE COVID-19 PUBLIC
HEALTH EMERGENCY 27 (2021).
128 Id. at 3-4.
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ii. Clinical Trial Participants’ Personal Data
A clinical trial for a new drug takes, in the United States, on average six
to seven years to complete. The number of volunteers may number in the
thousands. There are several actors that are involved in clinical trials (drug
developers, trial sponsors, researchers, etc.). Due to the nature of clinical
trials and the increasing number of actors involved therein, data obtained
from clinical trials is transferred horizontally among the different actors.
In the United States, the legal protection of clinical trial data is set forth
in the FDA regulations and the FDA Common Rule.129 The U.S. Department
of Health and Human Services (HHS) is responsible to promulgate
regulations for the privacy of individuals’ health data.130 The privacy rule
under the Health Insurance Portability and Accountability Act (HIPAA)
ensures individual health data is protected when transmitted between
healthcare providers and health insurance providers. Pharmacists and drug
manufacturers are not identified as a covered entity within the scope of the
HIPAA privacy rule. The US Supreme Court in Sorrell v. IMS Health Inc131
held that a Vermont statute that restricts the communication of health
information collected from patients is unconstitutional.132 The privacy rule,
however, extends to clinical trial sponsors’ study teams.133 Under the HIPAA
protected health information is defined as individually identifiable health
information that is maintained or transmitted in any medium. This
“information” in the definition includes all oral, recorded, past, present or
future physical or mental health or conditions of an individual. For the
purpose of research, protected health information, could be disclosed. 134 In
clinical trials any information obtained from volunteers would be classified
as health information and would be protected under the HIPAA privacy rule.
If the information obtained in a clinical trial is anonymized, it would not be
subject to HIPAA protection.135 HIPAA requires consent from the individual
to disclose or share his/her data.136 The individual should be notified of the
name/entity to whom the information is disclosed, the purpose of the
disclosure, an expiry date for the disclosure and the signature of the
individual authorizing the disclosure.137 The individual has the right to

See 45 C.F.R § 46.101 and 21 C.F.R. § 314.126.
U.S. DEP’T OF HEALTH AND HUMAN SERVS., SUMMARY OF THE HIPPA PRIV. RULE 1 (2003).
131 Sorrell v. IMS Health, 564 U.S. 552 (2011).
132 Id.
133 45 C.F.R. §160.103 (2013).
134
45 C.F.R. §164.152(i)(1)(iii) (2013).
135 45 C.F.R. §164.502(d)(1) (2013).
136 45 C.F.R. §164.508(a) (2013).
137 45 C.F.R. §164.508(c)(1) (2013).
129
130
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revoke the authorization at any time.138 In 2011, the HHS sought to amend
the Common Rule to incorporate the HIPAA privacy rule to strengthen the
privacy protection of data obtained from human subjects during a clinical
trial.139
Under the European Union legal framework, clinical trials and data
protection regulations are generally governed by two distinct standards. The
volunteer’s informed consent to participate in a clinical trial is different from
the volunteer’s consent for lawful processing of his/her personal data. For
example, Article 56 of the European Clinical Trials Regulation (CTR)140
requires the clinical trial sponsor to record, store and handle data of the
clinical trial protocol while preserving the confidentiality of the records to
protect personal data. The CTR legally obliges the clinical trial sponsor to
report all results of the trial, perform safety reporting and archive the clinical
trials in a master file for twenty-five years. The clinical trial protocol must
define the purpose and conditions under which data collected from clinical
trial participants will be processed. The volunteers should be properly
informed on the processing of their personal data. The sponsor of the clinical
trial is the data controller and is obliged to institute measures to ensure that
the data is processed in accordance with the rules of the General Data
Protection Regulation (GDPR).141 Processing of clinical trial data for the
purpose of reliability and safety must be in compliance with Article 9(2)(i)
of the GDPR, which provides that:
Processing is necessary for reasons of public interest in the
area of public health such as ensuring high standards of quality and
safety of health care and medicinal products or medical devices,
on the basis of Union or member State law, which provides for
suitable measures to safeguard the rights and freedoms of the data
subject, in particular professional secrecy.
The legal obligation of the clinical trial sponsor is that expressed in the
CTR relating to the safety reporting under Articles 41-43 and archiving
45 C.F.R. §164.508(b)(5) (2013).
Human Subjects Research Protection: Enhancing Protection for Research Subjects and
Reducing Burden, Delay and Ambiguity for Investigators, 76 Fed. Reg. 143, 44515 (July 26,
2011).
140 Council Regulation 536/2014 of Apr. 16, 2014, on Clinical Trials on Medicinal Products
for Human Use, 2014 O.J. (L 158) 41.
141
Council Regulation 2016/679 of Apr. 27, 2016, on the Protection of Natural Persons with
Regard to the Processing of Personal Data and on the Free Movement of Such Data (GDPR),
2016 O.J. (L 119) 30, 46.
138
139
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under Article 58. The legal basis for data processing related to reliability and
safety purposes under the GDPR, states that processing of data collected
from clinical trials is lawful if it is “necessary for compliance with a legal
obligation to which the controller (sponsor of the clinical trial) is subject.”
Processing of clinical trial data for research activities is derived from a legal
obligation in accordance with Article 9(2) in conjunction with Article 6(1)
of the GDPR for either public interest, legitimate interest or under specific
circumstances.
There is a fundamental distinction concerning the definition of informed
consent in view of data processing between the CTR and the GDPR. The
CTR considers informed consent as a safeguard, not a legal basis, for data
processing while under the GDPR informed consent is a legal obligation.
Thus, under the GDPR, consent must be: freely given, specific, informed and
unambiguous; hence processing of data under specific circumstances
requires an explicit consent from the participant. This difference between the
CTR and GDPR requirements has a substantial effect on data collected from
a participant in a clinical trial in the event that the participant decides to
withdraw. Under Article 28(3) of the CTR withdrawal from a clinical study
does not affect the data obtained on the basis of the informed consent before
the withdrawal. On the contrary, under the GDPR when the individual
participant withdraws its consent all data obtained must be deleted by the
controller.142
The GDPR applies to clinical trial sponsors established in the European
Union (EU) and outside the EU where the processing is related to data
subjects of the EU.143 Thus, both HIPAA and the GDPR will impact clinical
trials conducted in the EU and sponsored by US companies (e.g. Pfizer
testing of mRNA in Germany). Although HIPAA and the GDPR regulate the
collection and transfer of clinical trial participants’ data these regulations
differ in several areas. HIPAA obtains the authorization to collect, process
and transfer data in the informed consent to participate in the clinical trial
while the GDPR through an informed consent process specifically designed
for the data to be collected, processed and transferred between entities. The
HIPAA authorization must include details of the purpose and the entities that
will use the data, but HIPAA does not specify exactly how much detail must
be communicated with a clinical trial volunteer. The GDPR, however,
requires that volunteers are provided with sufficient information to make a
knowledgeable decision. The GDPR provides an absolute right to clinical
trial volunteers to revoke data processing, whereas the HIPAA provides a

142
143

See GDPR art. 3, 17(1)(b), 2016 O.J. (L 119) 32, 43.
See GDPR arts. 3, 27, 2016 O.J. (L 119) 32, 48.
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volunteer the right to revoke an authorization, albeit it permits a limitation if
the authorization has been relied upon.144
Exceptional deviation from data protection regulations (e.g. HIPAA in
the US and the GDPR in the EU) under a state of emergency provides some,
but not unlimited authority, to relax protections concerning privacy of
information.145 Governments operating under a state of emergency possess
the legislative means to use clinical data to restore public health without
acquiring individual consent. For example, the UK enacted a special law
entitled: “The Health Protection (Coronavirus) Regulation 2020”,146 which
granted powers to health care providers, among other entities, to confine,
treat and transmit personal information of Covid-19 infected individuals
without their consent. The powers become effective upon a declaration by
the Secretary of State declaring an imminent threat to public health. In
similar manner, Germany promulgated a Coronavirus Notification
Regulation,147 governing the use of personal data associated with the virus
infection. Health care providers are permitted to transmit personal
information to a competent authority to allow for coronavirus outbreak
analysis without the consent of the individual.

V. BLOCKCHAIN AND RISK GOVERNANCE REGISTRY
Blockchain is a form of digital information stored in a public database.
Blockchain is based on the ledger keeping method that is distributed across
many stations, through a peer-to-peer network, which functions on the basis
of a cryptographic communication scheme to ensure the security of its
records.148 All connected peers hold identical copies of the ledger machine
consensus.149 While bitcoin (or cryptocurrency) is the most recognized
application of blockchain, many other applications are being advanced,
45 C.F.R. §164.508(b)(5) (2013).
See Disclosures for Public Health Activities, OCR HIPAA PRIVACY (Apr. 3, 2003),
https://www.hhs.gov/hipaa/for-professionals/special-topics/public-health/index.html.
146 See The Health Protection (Coronavirus) Regulations 2020, SI 2020/129, (Eng.),
http://www.legislation.gov.uk/uksi/2020/129/made.
147 See Coronavirus and Basic Rights: What is the German State Allowed to do?, DW,
https://www.dw.com/en/coronavirus-and-basic-rights-what-is-the-german-state-allowed-todo/a-52835004.
148 A. Cohn, T. West, & C. Parker, Smart After All: Blockchain, Smart Contracts, Parametric
Insurance, and Smart Energy Grids, 67 Defense L.J. 57 (2018).
149
J Yli-Huumo et al. 'Where Is Current Research on Blockchain Technology?—A Systematic
Review' (2016) 11(10) PloS 1. J. Yli-Huumo et al., Where Is Current Research on Blockchain
Technology?—A Systematic Review, 11(10) PloS 1 (2016).
144
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particularly in the context of sharing inter-organizational data, digital asset
registration or integrity, and identity management.150 To simplify the concept
of blockchain in risk registry of nano-carriers in transnational clinical trials,
consider the blockchain of risk registry as a computer file. The file is stored
in a computer in the network, say a location where the clinical trial is being
carried out. The file is broadcasted to other locations on the network of
transnational clinical trials for risk register sharing and updates. The risk
registry generated from one transnational clinical trial location will be shared
with all on users (e.g. other locations and regulators of foreign and domestic).
The blockchain ensures the integrity and security of the information because
it is built on a system of distributed consensus. This does not allow changes
unless all participants agree to the change.151
There are three main categories of blockchains, which are largely public
blockchain where access to join the network is granted to anyone with an
intent to join the network. Upon joining, the participant is enabled to add
information, approving tasks or make new additions to the ledger.152 Private
or permissioned blockchains exist where a new user can only join a network
through an invitation scheme that checks whether the new user meets a set
of conditions established by the peer-to-peer network. Once access is
granted, the new user will be provided with authentication, access control
and privileges.153 Consortium blockchain exists where a semi-decentralized
data structure is controlled by a single organization in the same fashion as
that of the permissioned blockchain. This scheme is utilized to manage the
growth of the data file that is distributed across the network and act as a
consensus system for any new information to the ledger being handled by
the network.154
The distribution of data from a single database to distributed databases
increases decentralized control and storage of records that have the potential
to increase the trust and give rise to the collaborative system. By using
blockchain, the efficiency of the risk registry system will be increased and
result in better synchronization and countering the security issues and
availability of information.
M. Memon et al., Blockchain Beyond Bitcoin: Blockchain Tech. Challenges and RealWorld Applications, 29 IEEE (Aug. 2018).
151C. Mann et al., Two-Factor Authentication for the Bitcoin Protocol, 16 INT. J. INF. SECUR.
213 (2017).
152 N. K. Ostern, Blockchain in the IS Research Discipline: A Discussion of Terminology and
Concepts, 30 Electronic Markets 195 (2019).
153
T. I. Kiviat, Beyond Bitcoin: Issues in Regul. Blockchain Transactions, 65 DUKE L.J. 569
(2015).
154 M. Latha Nandi et al., Blockchain Technology-Enabled Supply Chain Sys. and Supply
Chain Performance: A Resource-Based View, 25 SUPPLY CHAIN MGMT. 841 (2020).
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Permissioned blockchain recording system provides protective access to
include new risk registries from clinical trial conductors from around the
globe. It also allows the producers to have a platform to gather all risk data
generated from all participants, thus subsequently improve the risk
governance which subsequently improves the informed consent. The
distributed feature of the blockchain ledger allows for collaborative sharing
of risk data by all of those sharing the data in a network consisting of all
participants of the outsourced clinical trials. Distributed ledgers allow all
clinical trials monitoring personnel (onsite or remotely) within the network
to access and visualize changes to the ledger as they occur while maintaining
the information safe from unauthorized access via cryptographic keys and
signatures.155 The technology represents an opportunity for evolution in
various fields of clinical trials risk governance given its adaptability to all
elements of risk governance. Transparency and disclosure are at the base of
good risk governance models in that they enable clinical trials participants
to make informed decisions.
Tracking risk governance registry for international clinical trials of
nano-enabled vaccines provides substantial advancement to materializing
new treatment regiments around the globe. It allows for robust and
standardized electronic trials data record-keeping that can be inspected by
regulators remotely. It allows for the identification of problems at the early
stage of the trial. The risk governance registry enables the recruitment of
volunteers and at the same time enables regulatory oversight for new vaccine
approvals.
A. BLOCKCHAIN AND RISK GOVERNANCE OF INFORMED CONSENT
Vaccine testing and approval process proceeds at different timecontrolled and efficacy stages. The first stage in the development cycle is the
exploratory stage followed by pre-clinical stage then clinical stage that is
followed by regulatory review and approval. Subsequently the vaccine will
be manufactured under quality control measures.
Clinical trials of the same vaccine could be running simultaneously at
different locations by different conductors. For example, efficacy clinical
trial for the mRNA-1273 vaccine, which was developed by ModernaTX, Inc.
is conducted at 100 different locations involving more than 30,000

A. Hughes et al., Beyond Bitcoin: What Blockchain and Distributed Ledger Technologies
Means for Firms, 62 BUSINESS HORIZONS 273 (2019).
155

Summer 2021

COVID-19 VACCINES AND THEIR PITFALLS

181

participants.156 It is well known that drugs could be tested at different
locations, often cross boundary from the manufacturer’s home state. For
example, Thermodox, is currently under twelve clinical trials testing efficacy
against liver, breast and bone cancer at different locations (United States,
United Kingdom, Netherland, China, and Canada).157 Johnson and Johns just
initiated its Phase 3 testing on its COVID-19 vaccine to include 60,000
participants from Argentina, Mexico, Chile, Colombia, South Africa and the
United States. Massive data will be generated out of these clinical trials.
Blockchain strategy for risk governance will enable collection of all data and
making available globally and on-time.
The blockchain ledger of all five risk governance elements (preassessment, appraisal, evaluation and tolerability, management and
communication) complies with recent ruling in the United States that
requires for all clinical data to be made available to healthcare providers and
patients. In Seife and Lurie v. U.S. Department of Health and Human
Services,158 the plaintiff claimed that “The basic reporting requirements
deprived them as well as other researchers and advocates, of the data
necessary to ensure transparency in research, promote better decisionmaking by clinicians and policymakers, eliminate bias in the medical
literature, and to make patients, clinicians, and regulators aware of medical
product safety and effectiveness.” The basic requirement for vaccine
approval under the FDA statues does not require that all data be made
available. However, the possibility of producers to may only share data that
in favor of their product is highly possible, leading to healthcare providers
to prescribe vaccines that are ineffective or unsafe. Extending this ruling to
pre-clinical data that is required for the recruitment of volunteers for clinical
trials improves immensely the informed consent practice, particularly for
nano-enabled mRNA COVID vaccine that definitely have higher uncertainty
and ambiguity due to its instability and immunogenicity.
Risk governance for nano-enabled vaccines need to run in parallel with
all stages of vaccine clinical trials. Blockchain ledgers associated with each
element of the risk assessment. A block that consists of index, timestamp,
list of risk data entry transactions, proof and a connector to other blocks.
The decentralized standard for transnational clinical trials risk registry
allows for the disclosure of registered risks among all participating sites, thus
A. Hughes et al., Beyond Bitcoin: What Blockchain and Distributed Ledger Technologies
Means for Firms, 62 BUSINESS HORIZONS 273 (2019).
157 Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast
Cancer
Recurrence
at
the
Chest
Wall,
Clinicaltrials,
https://clinicaltrials.gov/ct2/results?cond=cancer&term=ThermoDox&cntry=&state=&city=
&dist.
158 Seife v. HHS, 1:18-cv-11462 (S.D.N.Y. 2020).
156
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strengthening the components of informed consent and build trust between
international pharmaceutical vaccine producers and the governments where
the volunteers are recruited. Further it allows for the regulatory bodies to
have access to all relevant data ahead of pre-marketing approval. The
benefits of deploying blockchain technology of risk registry of vaccine nanocarriers could be summarized in the following points:
•

•

•
•

•
•

Transparency: Every node on the network will have a
complete documentation of the registered risk and holds
history of the registry that can be visible to all permissioned to
view anytime and from anywhere. Thus, clinical trials
directors at all locations will be able to view the risk and
inform potential volunteers or take actions to mitigate risks of
currently participating volunteers. It also, allows for the
regulators and government agents to review the risks as they
registered from all participating locations. Thus, facilitating
the administration of informed consent even at locations
where the risks have not yet been registered.
Build trust: Transnational clinical trials are painted with a
dark record of unethical behaviour of a number of
pharmaceutical key players. Regulatory bodies at different
locations may have different requirements to authorize clinical
trials in their territories, however, access of immutable risk
registry record keeping and verification of data at multiple
nodes facilitate trust building between transnational regulators
and global pharmaceutical industry.
Risk predictability: The risk history maintained at different
nodes and generated from clinical trials at different locations
facilitates prediction of risk at new clinical trials locations.
Reliability: The risk registry is stored at multiple nodes
through the blockchain system, the consensuses scheme
assures change of information only when other relevant peers
approve. Thus, tampering with risk registry is minimized.
Security: Data are stored at multiple nodes using encryption
which will prevent tampering with data without proper
authentication.
Ease of access: The availability of data at the distributed
nodes on the net enhances the ease and speedy access of risk
registry data.
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The challenges that may arise of employing blockchain technology to
risk governance of clinical trials that involve vaccine enabled with nanocarriers include:
•

•

•

IP protection of the technologies, not only the blockchain
platform, but also the vaccine and its nano-carriers. Volunteers
of the clinical trials, particularly those at developing countries,
are not concerned with IP infringements. The permission
blockchain could mitigate this concern by restricting shared
information to only those who are participating in the study
and only information pertaining to informed consent.
Confidentiality of the data, which includes the personal data
of the volunteers as well as the research data obtained at the
different phases of the trial. A new prescription drug value is
backed by the scientific evidence supporting the product.
Transparency of data ensures that all positive and negative
implications of the vaccine and its nano-drug be made
available to volunteers to make an informed decision.
Confidentiality of data to sponsor could be managed by
blockchain ledger to only allow for participants to view the
data. This is probably the most problematic challenge that
could face a producer, as it makes all of its data be potentially
available to its competitors. However, the producers are
legally bound by the informed consent doctrine to make all
data available to volunteers so they can make an informed
decision. The risk governance will ensure that only products
that meet the safety threshold to reach to state of efficacy
evaluation with human volunteers.
Regulatory measures to catch up with the advancement in both
the vaccine and its nano-carrier technology and that of the
blockchain. This essay contends that new regulatory
approaches are needed to address vaccine enabled with nanocarrier. Current regulatory measures are based on
extrapolation of conventional regulatory instruments to
rapidly address known concerns. However, those were
developed for technologies that are not viable at the nanoscale.
The risk governance provides a systematic approach for
designing balanced regulatory measure that on one hand
allows for new scientific discovery to progress and on the
other mitigate unnecessary exploitation of vulnerable
volunteers to unsafe drugs.
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The blockchain management of risk governance of vaccine enabled with
nano-carriers clinical trials provides a technological tool that increases
transparency, mitigate the legal claims associated with informed consent and
affirms the legal burden on both producers and host state to ensure that
uncertainties and ambiguities are addressed ahead of instituting drugs to
volunteers. Further, the approach helps all sites participating in clinical trials
to have direct and immediate access to data to manage risks that were
discovered at remotes sites.

VI. CONCLUSION
The coronavirus outbreak forced governments to declare states of
emergency. In search of a medical breakthrough that could either treat the
infection or reduce its spread, pharmaceutical companies engaged in a race
to identify vaccines that could be employed to reduce the effect of the
outbreak. mRNA vaccines have been identified as potential candidates. To
reduce the mRNA’s harmful impact, the vaccine was encapsulated in a nanoshell. Clinical trials on human subjects commenced at record speed.
Regulations that allow for fast tracking clinical trials have been enacted
under the exceptional power of governments acting under states of
emergency. A declared state of emergency must nonetheless account for the
integrity of the human volunteers, while at the same time encourage
development of a viable effective vaccine. The informed consent doctrine
and rigorous monitoring mechanisms of clinical trials are only two vital
elements among the many that are required to ensure the protection of
participants in mRNA clinical trials. Human rights oblige States to respect,
protect and fulfill the highest standards of health to clinical trials participants,
whether conducted locally or internationally. This right is non-derogable
even in a state of emergency. A risk governance framework mitigates
ambiguous risks and provides more informed consent to prenatal
participants, which on the one hand assists in recruiting informed volunteers,
while on the other reduces potential liability. Laws concerning personal data
protection are not immune from derogation during a national state of
emergency. The protections under the HIPAA and GDPR are fragile therein.
What is abundantly clear is that efforts to prevent spread of Covid-19, as
well as come up with a viable vaccine require not a relaxation of existing
human rights standards, but the augmentation of solidarity and international
cooperation. Blockchain technology would provide a registry ledger to
document risks and benefits in a way that could facilitate cross boundary
clinic trails for novel vaccine developers, government agencies and
volunteers.
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